zintick

Viking Therapeutics VKTX

Viking Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations

$25.36+1.89%close on Oct. 28, 2026 · volume 4.1M · Yahoo Finance

Price, last 47 sessions

$25.00$30.00$35.00$40.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $41.65 · low $24.21 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
July 29, 2026Brian Lian
President & CEO, director
Sold148,517$33.32$4.95 million
July 29, 2026Greg Zante
Chief Financial Officer
Sold21,217$33.47$710,141
July 29, 2026Marianna Mancini
Chief Operating Officer
Sold18,217$33.47$609,636

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 13 →
  • 8-KOct. 28, 2026, 4:10 p.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedViking Therapeutics Q3 2026 GAAP net loss per share of $1.55 widens from $0.81 and misses $1.06 consensus; cash rises to $960 million after offerings

  • 8-KSept. 28, 2026, 5:27 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Creation of a direct financial obligation · Financial statements and exhibits

  • 424B5Sept. 24, 2026, 9:05 p.m. ETView on SEC.gov
  • 424B5Sept. 24, 2026, 9:04 p.m. ETView on SEC.gov
  • 424B5Sept. 23, 2026, 5:13 p.m. ETView on SEC.gov
  • 424B5Sept. 23, 2026, 5:13 p.m. ETView on SEC.gov
  • 8-KSept. 22, 2026, 7:06 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

  • 4Aug. 7, 2026, 4:34 p.m. ETView on SEC.gov